

CURRICULUM VITAE

KATHERINE M. NEWTON, Ph.D.

ADDRESS: Center for Health Studies
1730 Minor Ave., Suite 1600
Seattle, WA 98101
TELEPHONE: (206) 287-2973
FAX: (206) 287-2871
E-MAIL newton.k@ghc.org

EDUCATIONAL BACKGROUND

PhD, Epidemiology, June, 1995
School of Public Health and Community Medicine
University of Washington, Seattle
Dissertation: "Postmenopausal Estrogen Replacement Therapy and Survival after Myocardial Infarction in Women"

MA, Nursing, March, 1977
University of Washington, Seattle
Thesis: "Comparison of Aortic and Brachial Cuff Pressures in Flat Supine and Lateral Recumbent Positions"

BSN, Highest Honors, June, 1972
University of California, San Francisco

CURRENT PROFESSIONAL POSITIONS

- 2005 - Associate Director for External Research, Group Health Cooperative Center for Health Studies, Seattle, WA
- 2007 - Senior Scientific Investigator, Group Health Cooperative Center for Health Studies, Seattle, WA
- 2005 - Affiliate Associate Professor, Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA
- 1999 - Affiliate Assistant Professor, Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, WA

PREVIOUS PROFESSIONAL POSITIONS

- 2002 - 2005 Associate Scientific Investigator, Group Health Cooperative Center for Health Studies, Seattle, WA
- 2000 - 2002 Acting Associate Scientific Director, Group Health Cooperative Center for Health Studies, Seattle, WA
- 1999 - 2004 Affiliate Assistant Professor, Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA

- 1997 - 2000 Assistant Investigator, Group Health Cooperative Center for Health Studies, Seattle, WA
- 1995 - 1997 Postdoctoral Fellow, Group Health Cooperative Center for Health Studies, Seattle, WA
- 1990 - 1995 Research Assistant, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
- 1990 - 1993 Teaching Assistant, Epidemiologic Methods III, Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA
- 1982 - 1989 Nurse Coordinator, Cardiothoracic Surgery, University of Washington Medical Center, Seattle, WA
- 1977 - 1982 Lecturer/Research Instructor, Department of Physiological Nursing, University of Washington, Seattle, WA
- 1972 - 1978 Staff nurse, Coronary & Cardiovascular intensive care, Veterans Administration Hospital, San Francisco, CA, & Providence Hospital Seattle, WA

SCHOLARSHIPS, FELLOWSHIPS, HONORS AND AWARDS

- 1969 - 1970 Regents Scholar, University of California, San Francisco
- 1975 Institutional Training Grant (NRSA), NIH, for pursuit of Masters Degree
- 1992 - 1994 Individual National Research Service Award, National Center for Nursing Research, Pre-doctoral Fellowship
- 1992 Presenter, Student Workshop, Society of Epidemiologic Research
- 1994 1994 Outstanding Student Scholarship Award
Department of Epidemiology, School of Public Health and Community Medicine
University of Washington, Seattle

PROFESSIONAL ACTIVITIES

Professional Organizations

- American Heart Association
 - Council on Cardiovascular Epidemiology
 - Council on Cardiovascular Nursing
- American Diabetes Association
- European Menopause and Andropause Society
- North American Menopause Society
- Society of Epidemiologic Research

Invited Participation in National/International Meetings

- March 2007 “Menopause and Sleep Problems.” Scientific Workshop on Women and Sleep sponsored by the National Sleep Foundation and the Atlanta School of Sleep Medicine, Washington, D.C.

- January 2007 "Principal Results of the Herbal Alternatives for Menopause Study." National Advisory Council on Aging Meeting, National Institute on Aging, Washington, D.C.
- Nov & July 2006 Conference on "New Interventions for Menopausal Symptoms – I & II," sponsored by National Institute on Aging, National Institutes of Health, Bethesda, MD.
- Sept 2006 "Northern Lights Workshop on CAM Use Registration," sponsored by The National Research Center in Complementary and Alternative Medicine, University of Tromso, Tromso, Norway.
- June 2006 "Hormone Therapy Re-Initiation and First-Time Initiation by Type, Dose and Route, After the Women's Health Initiative."
 "The Impact of Hormone Therapy and Herbal Remedies for Menopause Symptoms on Sleep Quality: The HALT Trial." 7th European Congress on Menopause, Istanbul, Turkey.
- January 2004 "Validity of Self Report Measures of Vasomotor Symptoms," Invited Speaker/Panelist, Workshop on Measurement of Vasomotor Symptoms, Sponsored by National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD.
- March 2003 "Menopause Basics," Sponsored by North American Menopause Society, American Association of Pharmacists, New Orleans, LA.
- May 2001 "Shared Decision Making: HRT as a Research Paradigm." HMO Research Network Conference. Seattle, WA.
- May 2001 "Creating opportunities with consumer and community-based research." Program Moderator. Building Bridges VII Research Conference, American Association of Health Plans, Seattle, WA..
- June 2000 "The epidemiology of menopause," and "Complementary and alternative strategies." Promoting Menopausal Health: Practical Clinical Guidelines. Association of Women's Health, Obstetric and Neonatal Nurses.
- 1997-1998 "Estrogen replacement therapy and prognosis after first myocardial infarction." Poster Sessions on Women and Heart Disease Sponsored by the American Heart Association. ACOG Scientific Sessions, Las Vegas, March 1997; American Association of Family Practice, Chicago, September, 1997; American Medical Women's Association, Chicago, November, 1997; American Heart Association Scientific Sessions, Orlando, November, 1997; NHLBI, Cardiovascular Health: Coming together for the 21st Century, San Francisco, February, 1998; American Heart Association Scientific Sessions, Dallas, November, 1998.
- May 1998 "The use of alternative and complementary medicine by women enrolled in an HMO setting." Fourth Annual HMO Research Network Conference, Oakland, CA.
- May 1998 "Obesity and Postmenopausal Hormones." Obesity: Impact on Cardiovascular Disease. American Heart Association sponsored workshop. Amelia Island, Florida.

- September 1998 “Promoting Informed Decision Making During mid Life: Examples from Canada and the United States.” North American Menopause Society, Toronto, Canada.
- November 1998 “Risks and Benefits of Hormone Replacement Therapy: Beyond CAD.” American Heart Association Scientific Sessions. Dallas, TX.
- August 1997 “The effects of estrogen replacement therapy on prognosis in women with coronary heart disease.” National Medical Association, Honolulu, Hawaii.

Invited Lectures

- October 2008 “Lessons Learned from the Herbal Alternatives Trial” Institute of Translational Health Sciences, University of Washington, Seattle, WA.
- April 2008 “Primary Findings from the Herbal Alternatives Study,” Bastyr University Research Conference, Seattle, WA
- October 2007 “Primary Outcomes form Herbal Alternatives Study,” Department of Epidemiology, University of Washington School of Public Health and Community Medicine, Seattle WA.
- April 2007 “Herbal Alternatives for Menopause Symptoms.” Complementary and Alternative Medicine and Center for Women’s Health and Gender Research Program, University of Washington School of Nursing, Seattle, WA.
- March 2006 “The Herbal Alternative HALT Study: A randomized trial of black cohosh, multibotanical herbs and dietary soy for vasomotor symptoms.” Human Nutraceutical Research Unit, University of Guelph, Guelph, Ontario, Canada.
- May 2004 “Alternative therapies for mid-life women: issues and research opportunities.” 10th Annual HMO Research Network Conference, Dearborn, MI, May 4, 2004.
- May 2001 “Attitudes and knowledge about future risk of type 2 diabetes and diabetes prevention among women with prior GDM and their health care providers.” Western Diabetes in Pregnancy Study Group. Skamania, WA.
- May 2001 “Hormone Replacement Therapy and Alternative Therapies for Menopause.” Continuing Nursing Education, University of Washington, Seattle, WA.
- February 1999 “Hormone Replacement Therapy, Has the pendulum swung the other way?” Continuing Nursing Education, University of Washington, Seattle, WA.

- October 1998/99 “The Epidemiology of Menopause.” Reproductive Epidemiology, Department of Epidemiology, School of Public Health and Community Medicine, University of Washington.
- October 1998 “Informed decision making about hormone replacement therapy in a managed care setting.” Department of Biobehavioral Nursing and Health Care Systems. School of Nursing, University of Washington, Seattle, WA.
- March 1998 “Informed decision making about hormone replacement therapy in a managed care setting.” Center for Women’s Health Research, School of Nursing, University of Washington.
- January 1998 “What factors account for differences in HRT prescribing by healthcare providers? The physician’s role in women’s decision making about hormone replacement therapy – The EnPOWER provider survey.” The Future of Managed Care and Women’s Health: New Directions for the 21st Century, The U.S. Public Health Service’s Office on Women’s Health, Washington D.C.

Editorial Reviews

American Journal of Epidemiology
 American Journal of Managed Care
 Annals of Internal Medicine
 Archives of Internal Medicine
 Diabetes Care
 Expert Review of Obstetrics and Gynecology
 Journal of Cardiac and Pulmonary Rehabilitation
 Journal of Clinical Epidemiology
 Journal of Managed Care
 Journal of the Society of Integrative Oncology
 Journal of Women’s Health & Gender Based Medicine
 Maturitas
 Obstetrics and Gynecology
 Women’s Health Issues

Grant Reviews

- 2008 Behavioral Science, Epidemiology & Prevention Committee, American Heart Association, Dallas TX.
- 2008 National Institute of Diabetes and Digestive and Kidney Diseases, Special Emphasis Panel, National Institutes of Health.
- 2007 National Institute of Diabetes and Digestive and Kidney Diseases, Special Emphasis Panel, National Institutes of Health.
- 2006 National Institute of Diabetes and Digestive and Kidney Diseases, Special Emphasis Panel, National Institutes of Health.
- 2005 National Center for Complementary and Alternative Medicine, Special Emphasis Panel, Additional Clinical Science, National Institutes of Health.

- 2004 Ad Hoc Reviewer, Aging Study Group 01, National Institutes of Health.
- 2004 Centers for Disease Control and Prevention. Prevention Center Research Program, 2004 External Review for Prevention Center Proposals.
- 2003 National Heart Lung and Blood Institute, Special Emphasis Panel review of Unsolicited Proposal, National Institutes of Health.
- 2003 National Center for Complementary and Alternative Medicine, Special Emphasis Panel, National Institutes of Health.
- 2001 Centers for Disease Control and Prevention, Prevention Center Research Program, 2001 External Review – Special Emphasis Panel.
- 2000-2003 Behavioral Science, Epidemiology & Prevention Study Group, American Heart Association, Dallas, TX (Co-Chair, 2002-3).
- 1999 Alliance of Community Health Plans 1999.
- 1999 HMO Research Network 1999.

Professional Service

- 2007 Convener, HMORN Diabetes Research Consortium Meeting, American Diabetes Association Scientific Sessions Meeting, Chicago.
- 2003-present Member, Data and Safety Monitoring Committee, “Glutathione Transferases in Humans” (2EAT) study. Johanna Lampe, PI. Fred Hutchinson Cancer Research Center.
- 2002-2005 Chair, Scientific Policy Committee, Center for Health Studies, Group Health Cooperative.
- 2002-present Member, Research Quality Liaison Committee, Group Health Cooperative.
- 2002-present Member, Integrating CAM: Nursing Emphasis (CAM and Nursing) Advisory Committee, University of Washington, School of Nursing.
- 2004-2005 North American Menopause Society, Abstract Reviewer.
- 2002-2003 North American Menopause Society, commentary for Menopause News, an email service providing summaries and commentary about recent scientific publications.
- 2000-2002 Member, Scientific Policy Committee, Center for Health Studies, Group Health Cooperative.
- 2000-2002 Member, Professional Education Committee, North American Menopause Society.
- 1999-2004 Reviewer “NAMS Menopause Core Curriculum Study Guide,” North American Menopause Society.
- 1989 & 1990 Co-chair, Scientific Symposium Planning Committee American Heart Association Washington Affiliate.
- 1990 Healthcare Site Committee, AHA Washington Affiliate.

- 1990 Women and Heart Disease Task Force, AHA Washington Affiliate.
- 1989-1990 Admission Committee, Department of Epidemiology, University of Washington.

Community Service

- 2007 Invited Speaker, Group Health Senior Caucus Annual Meeting, "How the Center for Health Studies transforms health care at Group Health and around the world."
- 1998-2005 Member, Heart Care Roadmap Team, Group Health Cooperative of Puget Sound.
- 2000-2002 Member, Diabetes Roadmap Team, Group Health Cooperative of Puget Sound.
- 2003 Invited Speaker, GHC Community Forum, Burien Clinic, "Getting to the Heart of the Matter."

BIBLIOGRAPHY

Research Papers in Refereed Journals

1. Sivarajan ES, Bruce RA, Almes MJ, Green B, Belanger L, Lindskog BD, **Newton KM**, Mansfield LW. In-hospital exercise after myocardial infarction does not improve treadmill performance. *New England Journal of Medicine* 1981;305:357-362.
2. **Newton KM**. Comparison of aortic and brachial cuff pressures in flat supine and lateral recumbent positions. *Heart and Lung* 1981;10:821-826.
3. Sivarajan ES, **Newton KM**, Almes MJ. Limited effects of out-patient teaching and counseling after myocardial infarction: a controlled study. *Heart and Lung* 1983;12:65-73.
4. Ott CR, Sivarajan ES, **Newton KM**, Almes MJ, Bruce RA, Bergner M, Gilson BS. A controlled randomized study of early cardiac rehabilitation: The Sickness Impact Profile as an assessment tool. *Heart and Lung* 1983;12:162-170.
5. **Newton KM**, Sivarajan ES, Clark JL. Patient perceptions of risk factor changes and cardiac rehabilitation outcomes after myocardial infarction. *Journal of Cardiac Rehabilitation* 1985;5:159-168.
6. Moore KI, **Newton KM**. Orthostatic heart rates and blood pressures in healthy young women and men. *Heart and Lung* 1986;15:611-617.
7. **Newton KM**, Killien MG. Patient/spouse learning needs during recovery from coronary artery bypass. *Progress in Cardiovascular Nursing* 1988;3:62-69.
8. Froelicher ES, Kee LL, **Newton KM**, Lindskog B, Livingston M. Return to work, sexual activity, and other activities after acute myocardial infarction. *Heart Lung* 1994;23:423-35.
9. Jick H, Derby LE, Myers MW, Vasilakis C, **Newton KM**. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. *Lancet* 1996;348:981-83.
10. **Newton KM**, LaCroix AZ. The association of body mass index with reinfarction and survival after first myocardial infarction in women. *J Women's Health*, 1996;5:433-44.

11. **Newton KM**, LaCroix AZ, McKnight B, Knopp RH, Siscovick DS, Heckbert SK, Weiss NS. Estrogen replacement therapy and prognosis after first myocardial infarction. *Am J Epidemiol*, 1997;145:269-77.
12. **Newton KM**, LaCroix AZ, Leveille S, Rutter C, Keenan NL, Anderson LA. Women's beliefs and decisions about hormone replacement therapy. *J Women's Health* 1997;6:459-465.
13. Leveille S, LaCroix AZ, **Newton KM**. Older women and hormone replacement therapy: Factors influencing late life initiation. *J Am Geriatr Soc* 1997;45:1496-1500.
14. LaCroix AZ, **Newton KM**, Leveille SG, Wallace J. Healthy aging: a women's issue. *West J Med* 1997;167:220-232.
15. Kaplan RC, Heckbert SR, Weiss NS, Wahl PW, Smith ML, **Newton KM**, Psaty BM. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. *Diab Care* 1998;21:1117-1121.
16. **Newton KM**, LaCroix AZ, Leveille S, Rutter C, Keenan NL, Anderson LA. The physician's role in women's decision making about hormone replacement therapy. *Obstet Gynecol* 1998;92:580-4.
17. Buist DSM, LaCroix AZ, **Newton KM**, Keenan NL. Are long-term hormone replacement therapy users different from short-term and never users? *Am J Epidemiol* 1999;149:275-81.
18. Ramsey SD, **Newton KM**, Blough D, McCulloch D, Sandhu N, Reiber GE, Wagner EH. Incidence, outcomes and costs of foot ulcers in patients with diabetes. *Diab Care* 1999;22:382-387.
19. **Newton KM**, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C. The use of automated data to identify complications and comorbidities of diabetes: a validation study. *J Clin Epidemiol* 1999;52:199-207.
20. Anderson LA, Caplan LS, Buist DSM, **Newton KM**, Curry SJ, Scholes D, LaCroix AZ. Perceived barriers and recommendations concerning hormone replacement therapy counseling among primary care providers. *Menopause* 1999;6:161-166.
21. Ramsey SD, **Newton KM**, Wagner EH, McCulloch D, Evans R. Patient-level estimates of the cost of diabetes complications in diabetes in a managed care population. *Pharmacoeconomics* 1999;16:285-295.
22. LaCroix AZ, **Newton KM**, Buist DSM, Curry SJ, Scholes D, Anderson LA, Keenan NL. . Population-based strategy for improving informed decision making about hormone replacement therapy in managed care settings. *Women's Health Issues* 1999;9:306-318.
23. Buist DSM, LaCroix AZ, **Newton KM**, Keenan NL. Long-term HRT users. *Menopause Digest* 2000;12:210-221.
24. Greenlund KJ, Keenan NL, Anderson LA, Mandelson MT, **Newton KM**, LaCroix AZ. Does provider prevention orientation influence female patients' preventive practices? *Am J Prev Med*. 2000;19:104-10.
25. Phelan EA, Buist DSM, Anderson LA, **Newton KM**, Delaney KM, LaCroix AZ. Understanding Attitudes of Older Women Towards Hormone Replacement Therapy. *Preventive Medicine* 2001;32:49-56.

26. Wagner EH, Sandhu N, **Newton KM**, McCulloch DK, Ramsey SC, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. *JAMA* 2001;285:182-189.
27. Van Kessel K, Reed S, Newton K, Meier A, Lentz G. The Second Stage of Labor and Stress Urinary Incontinence. *Am J Obstet Gynecol* 2001;184:1571-5.
28. Mueller BA, **Newton K**, Holly EA, Preston-Martin S. Residential water source and the risk of childhood brain tumors. *Environ Health Perspect* 2001;109:551-556.
29. **Newton KM**, LaCroix AZ, Buist DSM, Anderson LA, Delaney K. What Factors Account for Hormone Replacement Therapy Prescribing Frequency? *Maturitas* 2001;39:1-10.
30. **Newton KM**, LaCroix AZ, Buist DSM, Anderson LA, Delaney KM. Women's responses to a mailed Hormone Replacement Therapy workbook. *Menopause* 2001;8:361-7.
31. **Newton KM**, Buist DSM, LaCroix AZ, Keenan NL, Anderson LA. Use of alternative therapies for menopause symptoms: results of a population-based survey. *Obstet Gynecol* 2002;100:18-25.
32. Kim C, **Newton KM**, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care* 2002;25:1862-8.
33. Adams KF, **Newton KM**, Chen C, Emerson SS, Potter JD, White E, Lampe JW. Soy isoflavones do not modulate circulating insulin-like growth factor concentrations in an older population in an intervention trial. *J Nutr.* 2003;133:1316-9.
34. **Newton, KM**, LaCroix AZ, Heckbert SR, Abraham L, McCulloch D, Wagner EH, Barlow W. Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes. *Diabetes Care.* 2003; 26:2810-6.
35. Adams KF, Chen C, **Newton KM**, Potter DJ, Lampe JW. Soy isoflavones do not modulate prostate-specific antigen (PSA) concentrations in older men in a randomized controlled trial. *Cancer Epidemiol Biomarkers Prev.* 2004;13:644-8.
36. Valk GD, Renders CM, Kriegsman DM, **Newton KM**, Twisk JW, van Eijk JT, van der Wal G, Wagner EH. Quality of care for patients with type 2 diabetes mellitus in the Netherlands and the U.S. A comparison of two quality improvement programs. *Health Serv Res.* 2004;39:709-25.
37. Sullivan M, **Newton K**, Hecht J, Russo JE, Spertus JA. Depression and health status in elderly patients with heart failure: A 6-month prospective study in primary care. *Am J Geriatric Cardiology.* 2004;13:252-260.
38. Buist DSM, **Newton KM**, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield DL, Wei F, Pettus PT, Chan AK, Larry Kessler L. Hormone therapy prescribing patterns in the United States. *Obstet Gynecol.* 2004;104(5 Pt 1):1042-50.
39. Reed SD, **Newton KM**, LaCroix AZ. Indications for hormone therapy: the post-Women's Health Initiative era. *Endocrinol Metab Clin North Am.* 2004;33:691-715.
40. Melville J, Katon, W Delaney K, **Newton K**. Urinary Incontinence in U.S. Women: A Population-Based Study. *Arch Intern Med.* 2005;165:537-42.

41. **Newton KM**, Buist DSM, Miglioretti DL, Beverly K, Hartsfield DL, Chan KA, Andrade SE, Wei F, Connelly MT, Kessler L. The Impact of Comorbidities on Hormone Use After the 2002 Release of the Women's Health Initiative. *J Gen Intern Med* 2005;20:350-6.
42. **Newton KM**, Reed SD, Grothaus L, Ehrlich K, Guiltinan J, Ludman E, LaCroix AZ, The Herbal Alternatives for Menopause (HALT) Study: Background and Study Design. *Maturitas* 2005;52:134-46.
43. Adams KF, Lampe PD, **Newton KM**, Ylvisaker JT, Feld A, Myerson D, Emerson SS, White E, Potter JD, Lampe JW. Soy protein containing isoflavones does not decrease colorectal epithelial cell proliferation in a randomized controlled trial. *Am J Clin Nutr*, 2005;82:620-626.
44. Melville JL, Delaney K, **Newton K**, Katon W. Incontinence Severity and Major Depression in Incontinent Women. *Obstet Gynecol* 2005;106:585-92.
45. Hartsfield CL, Connelly MT, **Newton KM**, Andrade SE, Wei FeiFei, Miglioretti DL, Buist DSM. Health System Responses to the Women's Health Initiative Findings on Estrogen and Progestin: Organizational Response. *J Natl Cancer Inst Monogr*. 2005;35:113-115.
46. Wei F, Miglioretti DL, Connelly MT, Andrade SE, **Newton KM**, Hartsfield DL, Chan KA, Buist DSM. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. *J Natl Cancer Inst Monogr*. 2005;35:106-112.
47. Melville JL, Fan MY, **Newton K**, Fenner D. Fecal Incontinence in U.S. Women: A Population-Based Study. *Am J Obstet Gynecol* 2005;193:2071-6.
48. Melville JL, **Newton K**, Fan MY, Katon W. Health care discussions and treatment for urinary incontinence in U.S. women. *Am J Obstet Gynecol*. 2006;194:729-37.
49. **Newton KM**, LaCroix AZ, Levy L, Li SS, Qu P, Potter JD, Lampe JW. Soy protein and bone mineral density in older men and women: A randomized trial. *Maturitas* 2006;53:270-7.
50. Reed SD, **Newton KM**, Thompson LB, McCrummen BA, Warolin AK. The incidence of repeat uterine surgery following myomectomy. *J Women's Health*, 2006;15:1046-52.
51. Thompson LB, Reed SD, McCrummen BK, Warolin AK, **Newton KM**. Leiomyoma characteristics and risk of subsequent surgery after myomectomy. *Int J Gynaecol Obstet* 2006;95:138-43.
52. **Newton KM**, Reed SD, LaCroix AZ, Grothaus L, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo. A randomized trial. *Ann Intern Med* 2006;145:869-79.
53. Spangler L, **Newton KM**, Grothaus LC, Reed SD, Ehrlich K, LaCroix AZ. The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin. *Maturitas* 2007;57:195-204.
54. Reed SD, **Newton KM**, LaCroix AZ, Grothaus L, Ehrlich K. Night sweats, sleep disturbance, and depression associated with diminished libido in late menopause transition and early postmenopause: baseline data for the Herbal Alternatives for Menopause Trial (HALT). *Am J Obstet Gynecol*. 2007;196:593.e1-7.

55. Reed SD, **Newton KM**, LaCroix AZ, Grothaus L, Grieco V, Ehrlich K. Vaginal, endometrial and reproductive hormone findings: randomized placebo-controlled trial of black cohosh, multibotanical herbs and dietary soy for vasomotor symptoms, the herbal alternatives for menopause (HALT) study. *Menopause* 2008;15(1):51-8.
56. Bush TM, Bonomi AE, Nekhlyudov L, Ludman EJ, Reed SD, Connelly MT, Grothaus LC, LaCroix AZ, **Newton KM**. How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes. *J Gen Intern Med.* 2007; 22(9):1311-6.
57. Fialkow MF, **Newton KM**, Lentz GM, Weiss NS. Lifetime risk of surgical management for pelvic organ prolapse or urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008; 19(3):437-40.
58. Atkinson C, **Newton KM**, Bowles EA., Yong M, Lampe JW. Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in the United States. *Am J Clin Nutr.* 2008;87:679-87.
59. **Newton KM**, Buist DSM, Yu O, Hartsfield CL, Andrade SE, Wei F, Connelly MT, Chan KA. Hormone therapy initiation after the Women's Health Initiative. *Menopause.* 2008;15(3):487-93.
60. Carr DB, **Newton KM**, Utzschneider KM, Tong J, Gerchman F, Kahn SE, Heckbert SR. Modestly elevated glucose levels during pregnancy are associated with a higher risk of future diabetes among women without gestational diabetes. *Diabetes Care.* 2008;31(5):1037-9.
61. Spangler L, Scholes D, Brunner RL, Robbins J, Reed SD, **Newton KM**, Melville J, LaCroix AZ. Depressive symptoms, bone loss, and fractures in postmenopausal women. *J Gen Intern Med.* 2008;23(5):567-74.
62. Allison KH, Reed SD, Voigt LF, Jordan CD, **Newton KM**, Garcia RL. Diagnosing Endometrial Hyperplasia: Why is it so difficult to agree? *Am J Surg Pathol.* 2008;32(5):691-8.
63. Atkinson C, **Newton KM**, Stanczyk FZ, Westerlind KC, Li L, Lampe JW. Daidzein-metabolizing phenotypes in relation to serum hormones and sex hormone binding globulin, and urinary estrogen metabolites in premenopausal women in the United States. *Cancer Causes and Control.* 2008;19(10):1085-93.
64. Fialkow, MF, **Newton KM**, Weiss NS. Incidence of recurrent pelvic organ prolapse 10 years following primary surgical management: a retrospective cohort study. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008; 19(11):1483-7.
65. Melville JL, Wagner, LE, Fan MY, Katon WJ, **Newton KM**. Women's perceptions about the etiology of urinary incontinence. *J Womens Health (Larchmt).* 2008;17(7):1093-8.
66. Lee KA, Baker FC, **Newton KM**, Ancoli-Israel S. The influence of reproductive status and age on women's sleep. *J Womens Health (Larchmt).* 2008;17(7):1209-14.
67. Epplein M, Reed SD, Voigt LF, **Newton KM**, Holt VL, Weiss NS. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. *Am J Epidemiol.* 2008;168(6):563-70.

68. Atkinson C, **Newton KM**, Aiello Bowles EJ, et al. Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States. *Breast Cancer Res Treat.* 2008 Sep 28. [Epub ahead of print.]
69. Epplein M, Reed SD, Voigt LF, **Newton KM**, Holt VL, Weiss NS. Endometrial hyperplasia risk in relation to recent use of oral contraceptives and post-menopausal hormone therapy. *Ann of Epidemiol.* 2009;19:1-7.
70. Reed SD, Voigt LF, **Newton KM**, Garcia RH, Allison HK, Epplein M, Jordan D, Swisher E, Weiss NS. Progestin therapy of complex endometrial hyperplasia with and without atypia. *Obstet Gynecol.* 2009;113(3):655-62.
71. Reed SD, Ludman EJ, **Newton KM**, Grothaus LC, LaCroix AZ, Nekhlyudov L, Spangler L, Jordan L, Ehrlich K, Bush T. Depressive symptoms and menopausal burden in the midlife. *Maturitas.* 2009;62:306-10.
72. Spangler L, Reed SD, Nekhlyudov L, Grothaus LC, LaCroix AZ, **Newton KM**. Provider attributes associated with hormone therapy prescribing frequency. *Menopause.* 2009 Feb 18 [Epub ahead of print.]
73. Yong M, Atkinson C, **Newton KM**, Aiello Bowles EJ, Stanczyk FZ, Westerlind KC, Holt VL, Schwartz SM, Leisenring WM, Lampe JW. Associations between endogenous sex hormone levels and mammographic and bone densities in premenopausal women. *Cancer Causes Control.* 2009 Mar 13. [Epub ahead of print.]
74. Reed SD, **Newton KM**, Clinton WL, Epplein M, Garcia R, Allison K, Voigt LF, Weiss NS. Incidence of endometrial hyperplasia. *Am J Obstet Gynecol.* 2009 Apr 22. [Epub ahead of print.]
75. Reed SD, Buist DS, Anderson ML, Aiello Bowles EJ, Fitzgibbons D, Seger D, **Newton KM**. Short-term (1-2 mo) hormone therapy cessation before mammography. *Menopause.* 2009 May 15. [Epub ahead of print.]

Manuscripts Submitted

1. Carr DB, Newton KM, Utzschneider KM, Faulenback MV, Kahn SE, Easterling TR, Heckbert SR. Gestational diabetes or lesser degrees of glucose intolerance and risk of preeclampsia. *Am J Obstet & Gynecol.*
2. Carr DB, Newton KM, Hitti J, Utzschneider KM, Faulenbach MV, Kahn SE, Easterling TR, Heckbert SR. Preterm delivery and risk of future diabetes independent of preeclampsia or gestational diabetes. *Am J Obstet & Gynecol.*
3. Reed SD, Voigt LF, Newton KM, Garcia R, Allison HK, Epplein M, Jordan D, Swisher E, Weiss NS. Progestin treatment in relation to persistence or progression of complex endometrial hyperplasia with and without atypia. *Cancer J.*
4. Carr DB, Newton KM, Utzschneider KM, Tong J, Gerchman F, Kahn SE, Easterling TR, Heckbert SR. Preeclampsia and Risk of Developing Subsequent Diabetes. *Obstet & Gynecol.*

5. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, Voigt LF, Shenoy U, Ehrlich K, Weiss NS. Incidence of endometrial hyperplasia. Am J Obstet Gynecol/

Other Published Scholarly Papers

1. **Newton KM**. Coronary artery disease risk factors, in Contemporary Issues in Critical Care Nursing. S Woods (ed.) 1983, Churchill Livingstone.
2. Sivarajan ES, **Newton KM**. Exercise therapy, education and counseling for patients with coronary artery disease. Clinics in Sports Medicine 1984;3:349-369.
3. Killien MG, **Newton KM**. Longitudinal research-The challenge of maintaining continued involvement of participants. Western Journal of Nursing Research 1990;12:689-692.
4. **Newton KM**, Mottram K, Winegar C. The changing epidemiology of measles in Pierce County. Washington Public Health 10:54-56, 1992.
5. **Newton KM**, Froelicher ESS. Coronary Heart Disease Risk Factors, Chapter 14 in Cardiac Nursing, 3rd Ed. SL Woods, ESS Froelicher , CJ Halpenny, SU Underhill (eds) 1994, JB Lippincott Company.
6. **Newton KM**. Cardiac Catheterization, Chapter 24 in Cardiac Nursing, 3rd Ed. SL Woods, ESS Froelicher , CJ Halpenny, SU Underhill (eds) 1994, JB Lippincott Company.
7. La Croix AZ, **Newton KM**, Leveille SG, Wallace J. Healthy aging. A women's issue. West J Med 1997;167:220-32.
8. **Newton KM**, LaCroix AZ. Hormone replacement therapy and tertiary prevention of coronary heart disease. Menopausal Medicine 1998;6:5-9.
9. **Newton KM**. Obesity and postmenopausal hormones. Chapter 11 in Obesity: Impact on Cardiovascular Disease. DF Fletcher, SM Grundy, LL Hayman (eds) 1999, Futura Publishing Co., Inc.
10. **Newton KM**, LaCroix AZ, Buist DSM. Overview of Risk Factors for Cardiovascular Disease, Chapter 58 in Women and Health, MB Goldman and MC Hatch (eds), 2000, Academic Press.
11. **Newton KM**, Froelicher ESS. Coronary Heart Disease Risk Factors, Chapter 29 in Cardiac Nursing, 4th Ed. SL Woods, ESS Froelicher , SU Motzer (eds) 2000, JB Lippincott Company.
12. Musch MM, Juel R, **Newton KM**. Cardiac Catheterization, Chapter 18 in Cardiac Nursing, 4th Ed. SL Woods, ESS Froelicher, SU Motzer (eds) 2000, JB Lippincott Company.
13. **Newton KM**. Risk factors for coronary heart disease in women. Nsg Clin N Am 2004;39:145-63.
14. Reed SD, **Newton KM**, LaCroix AZ. Indications for Hormone Therapy, the Post-WHI Era. Endocrinol Metab Clin North Am. 2004;33:691-715.

Published Abstracts

1. **Newton KM**, Halpenny CJ, Stewart DK. Aortic and bilateral arm blood pressures in flat supine and lateral recumbent positions. *Circulation* 1978;58:II167.
2. **Newton KM**, Sivarajan ES, Bruce RA, Mansfield LW. Influence of a teaching/counseling program on patient's diet after myocardial infarction. *Circulation* 1981;64:IV-100.
3. **Newton KM**, Sivarajan ES, Bruce RA, Mansfield LW. Cost of hospitalization and loss of income following myocardial infarction. *Circulation* 1981;64:IV-187.
4. **Newton KM**, Sivarajan ES. Patient perceptions and predictions of risk factor changes and activity levels after myocardial infarction. *Circulation* 1983;68:III-327.
5. **Newton KM**, Killien MG. Expected vs. achieved benefits of patient/spouse after coronary artery bypass. *Circulation* 1986;74(part 2):II-488.
6. **Newton KM**, Killien MG. Quality of life during early recovery from coronary artery bypass. *Circulation* 1986;74(part 2):II-9.
7. **Newton KM**, Killien MG. Patient/spouse learning needs after coronary artery bypass. *Circulation* 1986;74(part 2):II-291.
8. **Newton KM**, Lazovich D, Mueller BA, Daling JR. The risk of low birth weight associated with smoking in consecutive pregnancies. Abstracts of the 118th Annual Meeting of the American Public Health Association 1990;Sept-Oct:203.
9. Miller B, Mueller B, Chu J, **Newton KM**, Beckman AM. Occurrence of past and present human papilloma virus infection in women with cervical intraepithelial neoplasia III. Abstracts of papers presented at the 11th International Papilloma Virus Workshop, Edinburgh, Scotland. 1992;Sept:276.
10. **Newton KM**, LaCroix AZ. The role of heart disease prevention in women's decisions regarding hormone replacement Therapy, The EnPOWER Study. *Circulation* (Suppl 1) 1996;94:I-12.
11. Buist DSM, LaCroix AZ, **Newton KM**. Long-term hormone replacement therapy (HRT) users; are they different and why do they persist? *Am J Epidemiol* 1997;145:S1.
12. **Newton KM**, Ramsey SC, Wagner EH, McCulloch DK, Sandhu N. The use of automated data to evaluate the complication burden of diabetes in a managed care setting. *Diabetes* (Suppl 1) 1997;46:142A.
13. Ramsey SD, Wagner EH, McCulloch DK, **Newton K**, Sandhu N. The cost of treating foot ulcers in patients with diabetes. *Diabetes* (Suppl 1) 1997;46:62A.
14. **Newton KM**, LaCroix AZ, Woods NF, Keenan NL, Anderson LA. Decisions about hormone replacement therapy among HMO women in the 1900's. *Menopause* 1996;3.
15. LaCroix AZ, **Newton KM**, Woods NF, Keenan NL, Anderson LA. To be or not to be on HRT in the 1990's: the roles of perceived risk, health history, and attitudes about menopause and HRT. *Menopause* 1996;3:

16. **Newton KM**, LaCroix AZ, Buist DSM. Do providers encourage HRT use for women at high risk of coronary disease? A focus on attitudes and prescribing behaviors. *Circulation(Suppl)* 1997;96:I-131.
17. **Newton KM**, Anderson LA, LaCroix AZ, Buist DSM, Keenan NL. Healthcare provider characteristics and encouragement to use HRT: The EnPOWER Provider Survey. *Menopause* 1997;4:263.
18. LaCroix AZ, **Newton KM**, Buist DSM, Keenan NL, Anderson LA. What factors account for differences in HRT prescribing by healthcare providers in a health maintenance organization? The EnPOWER Provider Survey. *Menopause* 1997;4:262.
19. Anderson LA, Caplan LS, Buist DSM, **Newton KM**, Curry S, LaCroix AZ. Counseling about HRT; Perceived barriers and recommendations among primary care providers. *Menopause* 1997;4:263.
20. **Newton KM**, LaCroix AZ, Buist DSM, Keenan NL. The use of alternative and complementary medicine by women enrolled in an HMO setting. *Menopause* 1998;4:254.
21. Reed S, **Newton K**. HRT in ethnic minority populations. *Menopause* 1999;6:355.
22. **Newton KM**, LaCroix AZ, Buist DSM, Anderson LA. Will women in managed care use a mailed HRT workbook? The EnPower workbook trial. *Menopause* 1999;6:347.
23. LaCroix AZ, Anderson LA, **Newton KM**, Buist DSM. Qualities of HRT counseling: Findings from the EnPower study. *Menopause* 1999;6:346.
24. **Newton KM**, Buist DSM, LaCroix AZ, Anderson LA. Attitudes towards uncertainty regarding HRT counseling: The EnPower Provider Survey. *Menopause* 2000;7:447.
25. Kim C, **Newton KM**, Knopp RH. Gestational diabetes and incidence of type 2 diabetes mellitus: a systematic review. *Soc Gen Int Med*;2001.
26. **Newton KM**, LaCroix AZ, Heckbert SR, Wagner EH, McCulloch DK, Barlow WE. Estrogen replacement therapy is associated with reduced risk of death and cardiovascular events in women with type 2 diabetes. *Diabetes* 2002(Suppl 2);51:A30.
27. Lampe JW, Levy L, Li SS, Qu P, **Newton KM**, LaCroix AZ. Effects of soy protein supplementation on spine and hip bone mineral density in an older population in a randomized controlled trial. *J Nutr* 2004;134:1289S.
28. **Newton KM**, LaCroix AZ, Reed SD, Grothaus LC, Lampe JW, Ehrlich K. Impact of herbal remedies for menopause on bone mineral density: The herbal alternatives for menopause (HALT) trial. *JBMR* 2007;22 (Supp 1):S117.
29. Spangler L, Scholes D, Brunner R, Robbins J, Reed S, **Newton K**, Melville J, LaCroix A. Is antidepressant use associated with bone loss or fractures in postmenopausal women. *JBMR* 2007;22 (Supp 1):S76.

Published Letters

1. LaCroix A, **Newton K**, Phelan E. Physician gender and estrogen replacement therapy. *JGIM* 1997;12:334.

2. Keenan NL, Anderson LA, LaCroix AZ, **Newton KM**, Buist DSM. Helping women achieve long-term continuance of estrogen replacement therapy (ERT) and hormone replacement therapy (HRT). *Menopause* 1999;6:179-80.
3. Reed S, **Newton K**, LaCroix A, Grothaus L. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. *Obstet Gynecol.* 2005;106:1111.
4. **Newton KM**, Reed SD, LaCroix AZ. Alternative Treatments of Vasomotor Symptoms of Menopause. *Ann Intern Med* 2007;147:346-7.
5. Reed S, **Newton KM**, LaCroix AZ, Grothaus L. In reply: Vaginal, endometrial and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) study. *Menopause* 2008;15(3):1.
6. Epplein M, Reed SD, Voigt LF, **Newton KM**, Holt VL, Weiss NS. Epplein et al. respond to: "Endometrial hyperplasia – Getting back to normal." *Am J Epidemiol* 2008;168:575-6.

RESEARCH HISTORY

Funded Research

- | | |
|---------------------|--|
| Title: | MSI-FLASH: An RCT of Yoga and Ultra Low-Dose Estrogen Gel for Vasomotor Symptoms |
| Role: | Co-Principal Investigator |
| Dates: | 09/10/2008-06/30/13 |
| Funding Agency: | NIH, National Institute on Aging |
| Total Direct Costs: | \$208,810 |
| Description: | Accelerate the identification of effective remedies for vasomotor symptoms in conjunction with NIH Menopause Symptoms Initiative and network and coordinating center (DCC) at Fred Hutchinson Cancer Research Center. Multicenter, factorial design, randomized controlled trial of yoga, ultra low-dose estradiol (E2) gel and placebo gel. |
| | |
| Title: | Epidemiology of Chronic Periodontitis and Diabetes Mellitus |
| Role: | Co-Investigator |
| Dates: | 12/01/07- 01/31/2010 |
| Funding Agency: | Washington Dental Service Foundation |

Total Direct Costs: \$450,298
Description: The goals of this study are to confirm and quantify the link between diabetes and chronic periodontitis and to explore the relationship between diabetes, diabetes outcomes and medical/dental care costs in a large HMO population.

Title: **HMO Research Network Cardiovascular Research Network**
Role: Group Health site Principal Investigator
Dates: 09/30/2007-06/30/2012
Funding Agency: NIH, National Heart, Lung, and Blood Institute
Total Direct Costs: \$180,921
Description: To establish a collaborative Cardiovascular Research Network (CVRN) among 14 member plans of the HMO Research Network to create a unique national resource that leverages the network's cardiovascular expertise, diverse community-based study populations, and rich electronic data systems.

Title: **Development and Use of Network Infrastructure for High-Throughput Genome Wide Association Studies**
Role: Co-Investigator
Dates: 09/27/2007-07/31/2011
Funding Agency: National Institutes of Health
Total Direct Costs: \$3,176,631
Description: This project will develop methods and create the infrastructure to perform high-throughput Genome Wide Analyses (GWA) in a population based sample of persons with Alzheimer's disease.

Title: **Health Care Improvement for Aging Women**
Role: Co-Investigator
Dates: 05/01/2007 – 04/30/2012
Funding Agency: NIH/NIA
Total Direct Costs: \$629,249
Description: The purpose of this training program is to prepare postdoctoral public health scientists (epidemiologists, health services researchers, behavioral scientists, and academic clinicians) to produce the evidence that will guide optimum, efficient, and cost-effective healthcare practices for older women. The overall goal is to create and maintain a comprehensive and scientifically productive training program with a plan for continuous evaluation and improvement.

Title: **Endometrial Hyperplasia – A Cohort Study**
Role: Co- Investigator
Dates: 04/1/2004 - 01/31/2008
Funding Agency: NIH
Total Direct Costs: \$172,441 (subcontract)

Description: The purpose of this 4-year cohort study is to establish rate of progression or persistence of the most severe forms of endometrial hyperplasia in response to progestin therapy or expectant management.

Title: **Breast and Bone Density: Impact of Colonic Environment**

Role: Co- Investigator

Dates: 05/6/03 - 04/30/07

Funding Agency: NCI

Total Direct Costs: \$740,113 (subcontract)

Description: The purpose of this study is to examine the relationship between equol-producer status and lifetime estrogen exposure (breast density and bone density, and markers of estrogen metabolism (ratio of 2-hydroxyestrone to 16 α hydroxyestrone:2OHE1:16 α -OHE1).

Title: **A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of HRT on Mammography Assessments and Breast Density**

Role: Co-Investigator

Dates: 06/1/2003 - 05/31/2006

Funding Agency: DOD

Total Direct Costs: \$226,336

Description: The purpose of this randomized trial is to evaluate the impact of HRT cessation for 1-2 months prior to a routine screening mammogram on the likelihood of receiving a recommendation for additional evaluation.

Title: **A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of HRT on Mammography Assessments and Breast Density**

Role: Co-Investigator

Dates: 06/1/2006 - 03/31/2008

Funding Agency: DOD

Total Direct Costs: \$242,229

Description: The purpose of this randomized trial is to evaluate the impact of HRT cessation for 1-2 months prior to a routine screening mammogram on the likelihood of receiving a recommendation for additional evaluation

Title: **HRT Initiation and Cessation Following Results from the Women's Health Initiative**

Role: Co-Investigator

Dates: 11/1/2002 - 10/31/2003

Funding Agency: NCI

Total Direct Costs: \$150,418

Description: The major goal of this study is to assess whether recent results from the Women's Health Initiative had an impact on the initiation or cessation of hormone replacement therapy in 5 HMO participants from the Cancer Research Network

Title: **Caring Intervention for Couples Who Miscarry**

Role: Co-Investigator
Dates: September 30, 2001 – September 29, 2005
Funding Agency: NIH
Total Direct Costs: \$37,603 (Subcontract)
Description: The purpose of this study is to examine the effect of a home-based intervention on emotional healing, integration of loss, and perceived couple well-being for women and their male partners after miscarriage.

Title: **Postmenopausal Evaluation and Risk Reduction with Lasofoxifene**
Role: Co- Investigator
Dates: April 2002 - March 2006
Funding Agency: Pfizer
Total Direct Costs: \$1,390,808
Description: The purpose of the industry-sponsored phase 3 clinical trial is to evaluate the safety and efficacy of a new selective estrogen receptor moderator in the treatment of osteoporosis in high-risk, postmenopausal women.

Title: **Postmenopausal Evaluation and Risk Reduction with Lasofoxifene**
Role: Co- Investigator
Dates: April 1, 2006 – March 31, 2008
Funding Agency: Pfizer
Total Direct Costs: \$145,518
Description: To continue long-term follow-up of risks and effectiveness of use of Lasofoxifene in post-menopausal women.

Title: **The impact and Cost of Female Bladder Dysfunction and Major Depression in a Primary Care Population**
Role: Co-Investigator
Dates: January 1, 2002 – January 31, 2003
Funding Agency: Upjohn/Pharmacia
Total Direct Costs: \$166,413 (subcontract)
Description: The purpose of this population-based survey is to establish the prevalence of incontinence among adult women enrollees of Group Health Cooperative, and to evaluate the association between urinary incontinence and depression.

Title: **Systems Approach to Improving Arthritis Clinical Care**
Role: Co-Investigator
Dates: December 1, 2000 – November 31, 2003
Funding Agency: Centers of Disease Control
Total Direct Costs: \$586,333
Description: The purpose of this study is 1) To develop an algorithm for identifying individuals with arthritis using administrative data; 2) To identify methods to define arthritis-related costs; and 3) To organize and facilitate a structured arthritis clinical care quality improvement initiative in state health departments.

Title: **Alternative Therapies for Menopause: A Randomized Trial**

Role: Principal Investigator
Dates: July 1, 2000 – November 30, 2006
Funding Agency: National Institute on Aging/National Center for Complementary and Alternative Medicine
Total Direct Costs: \$2,989,606
Description: The purpose of this double-blind randomized controlled trial is to evaluate the efficacy of three alternative approaches utilizing phytoestrogens to treat vasomotor symptoms in peri- and post-menopausal women.

Title: **Exercise to Improve Sleep in Heart Failure**
Role: Co-Investigator
Dates: February 1, 1999 – September 30, 2001
Funding Agency: National Center for Nursing Research
Total Direct Costs: \$63,930 (Subcontract)
Description: The purpose of this study is to investigate the effects of a low-level, nurse managed exercise intervention on sleep in patients with congestive heart failure.

Title: **Estrogen Replacement and CVD Outcomes in Diabetic Women**
Role: Principal Investigator
Dates: July 1, 1997 – June 6, 2001
Funding Agency: National Heart Lung and Blood Institute
Total Direct Costs: \$603,328
Description: A case-cohort study examining the association between hormone replacement therapy and coronary heart disease, lower extremity amputation and all-cause mortality in women with type 2 diabetes

Title: **Phytoestrogens and Colon Epithelium: A Randomized Trial**
Role: Co-Investigator
Dates: July 1, 1997 – March 31, 2002
Funding Agency: National Cancer Institute
Total Direct Costs: \$1,091,910
Description: A randomized, double-blind trial of the effect of dietary phytoestrogens on the estrogen receptor gene and on specific estrogen responsive genes.

Title: **An Association Between Prolonged Second Stage of Labor and Stress Urinary Incontinence – A Pilot Study**
Role: Co-Investigator
Dates: January 1, 1999 – July 31, 1999
Funding Agency: Department of Obstetrics and Gynecology, University of Washington (Fellowship award)
Total Direct Costs: \$13,116
Description: The purpose of this case-control study is to evaluate the association between prolonged second stage of labor, and other factors associated with labor, and the development of stress urinary incontinence.

Title: **EnPower Providers Follow-up Survey**
Role: Co-Investigator

Dates: September 1, 1999 – May 31, 2001
Funding Agency: Centers for Disease Prevention and Control
Total Direct Costs: \$100,000
Description: The purpose of this contract is to survey providers at Group Health Cooperative about the impact of the findings of the HERs study on HRT counseling, and to revise a consumer workbook for informed decision making about HRT.

Title: **EnPower Women’s Survey Follow-up Study: Women’s decision-making and health care provider counseling about the initiation, maintenance and cessation of hormone replacement therapy**

Role: Co-Investigator
Dates: September 1, 1997 – August 31, 1998
Funding Agency: Centers for Disease Prevention and Control
Total Direct Costs: \$60,000
Description: The purpose of this study is to investigate; 1) those factors that predict HRT use, 2) the prevailing reasons women initiate, maintain and or stop HRT, and 3) the nature of HRT counseling with health care providers.

Title: **Delivery of Preventive Services to Older Women in Managed Care Settings**

Role: Co-Investigator
Dates: September 1, 1996 – August 31, 1997
Funding Agency: Centers for Disease Prevention and Control – Prevention Center Grant
Total Direct Costs: \$194,898
Description: The long-term objective of this research was to improve health behaviors and rates of participation in preventive health services among older women enrolled at Group Health.

Title: **Assessment of Hormone Replacement Counseling and Colorectal Cancer Screening Among Older Women**

Role: Co-Investigator
Dates: September 1, 1996 – August 31, 1997
Funding Agency: Centers for Disease Prevention and Control
Total Direct Costs: \$100,000

Description: This was a supplemental request to the third year intervention trial of the CDC funded study “Delivery of Preventive Services to Older Women in Managed Care Settings.” The purpose of this proposal was to include GHC women in development and pilot testing of intervention materials and to increase the overall sample size.

Title: **Estrogen Replacement Therapy and Survival After Myocardial Infarction in Women**

Role: Principal Investigator
Dates: August 1, 1994 – March 31, 1996
Funding Agency: Wyeth-Ayerst Pharmaceuticals
Total Direct Costs: \$25,000

Description: The purpose of this retrospective cohort study was to test the hypothesis that estrogen replacement therapy decreases the risk of reinfarction and improves survival among women who survive a first myocardial infarction.

Title: **Estrogen Replacement Therapy and Survival after Myocardial Infarction in Women**

Role: Principal Investigator

Dates: September 1, 1992 – March 31, 1994

Funding Agency: Group Health Foundation

Total Direct Costs: \$15,000

Description: The purpose of this retrospective cohort study was to test the hypothesis that estrogen replacement therapy decreases the risk of reinfarction and improves survival among women who survive a first myocardial infarction.

Title: **Individual National Research Service Award**

Role: Student Recipient

Dates: September 1, 1992 – August 31, 1994

Funding Agency: National Center for Nursing Research

Total Direct Costs: \$25,666

Title: **Patient/Spouse Recovery from Coronary Artery Bypass Graft Surgery**

Role: Principal Investigator

Dates: March 1, 1984

Funding Agency: Sigma Theta Tau, National and Local Chapters

Total Direct Costs: \$4,000

Description: The purpose of this study was to describe patient and spouse learning needs, expected and achieved benefits, and emotional responses during the first six months following coronary artery bypass surgery.

Proposals Submitted and Pending

Title: **Equol and VMS**

Role: Principal Investigator

Dates: 01/01/2009 – 12/31/2010

Total Direct Costs: \$344,453

Funding Agency: Otsuka Pharmaceutical

Description: Examine effects of equol producer status and soy intake on vasomotor symptoms.

Title: **OSA and Metabolic Syndrome: The Impact of CPAP on Insulin Sensitivity**

Role: Co-Investigator

Dates: 04/01/2009 - 03/31/2011

Funding Agency: NIH
Total Direct Costs: \$233,274
Description: The purpose of this study is to determine, among patients with obstructive sleep apnea and metabolic syndrome with elevated fasting glucose levels, whether CPAP adherence 6-months after CPAP initiation is associated with improved insulin sensitivity (HOMA indices), decreased central adiposity (CT scan) and lower first morning blood pressure.

Title: **Pain during Menopausal Transition and Early Post-Menopause**
Role: Co-Investigator
Dates: 04/01/2009 – 3/31/2014
Funding Agency: NIH, National Institute on Aging
Total Direct Costs: \$233,274
Description: The overall goals of this research are to assess rates of and risk factors for specific chronic-recurrent pain problems, pain severity and personal and social impact as measured by key behaviors (activity limitation, use of prescription medications and health care visits for pain) during the early and late phases of the menopausal transition and the first 5 years post-menopause.

Title: **Perimenopausal Depression and Vasomotor Symptoms: A Longitudinal Cohort Study**
Role: Principal Investigator
Dates: 07/01/2009 – 06/30/2013
Agency: NIH, National Institute on Aging
Total Direct Costs: \$510,674
Description: The goal of this observational cohort study is to better understand how the experience of vasomotor symptoms is affected by current and past depression among women age 45-54 who are in the menopause transition or early post-menopause.

Title: **Systolic Blood Pressure Intervention Trial**
Role: Group Health Site Principal Investigator
Dates: 08/31/2009 – 08/30/2018
Total Direct Costs: \$93,149
Agency: NIH, National Heart, Lung, and Blood Institute
Description: The objective of the Systolic Blood Pressure Intervention Trial (SPRINT) is to conduct a multicenter, randomized clinical trial to determine whether treating systolic blood pressure (SBP) to a lower goal than currently recommended will reduce cardiovascular disease (CVD). The proposed trial will test the effects of intensive SBP lowering compared with standard lowering, specifically a comparison of a SBP goal of <120 mmHg versus <140 mmHg for a SBP difference of 10-15 mmHg between the two randomized groups.

SCIENTIFIC PRESENTATIONS

Newton KM, Sivarajan ES, Bruce RA, Mansfield LW. Influence of a teaching/counseling program on patient's diet after myocardial infarction. American Heart Association Scientific Session, November 1981.

Newton KM, Sivarajan ES, Bruce RA, Mansfield LW. Cost of hospitalization and loss of income following myocardial infarction. American Heart Association Scientific Session, November 1981.

Newton KM, Sivarajan ES. Patient perceptions and predictions of risk factor changes and activity levels after myocardial infarction. American Heart Association Scientific Session, November 1983.

Newton KM, Killien MG. Expected vs. achieved benefits of patient/spouse after coronary artery bypass. American Heart Association Scientific Session, November 1986.

Newton KM, Killien MG. Quality of life during early recovery from coronary artery bypass. American Heart Association Scientific Session, November 1986.

Newton KM, Killien MG. Patient/spouse learning needs after coronary artery bypass. American Heart Association Scientific Session, November 1986.

Newton KM, Lazovich D, Mueller BA, Daling JR. The risk of low birth weight associated with smoking in consecutive pregnancies. Annual Meeting of the American Public Health Association, New York, November, 1990.

Newton KM, LaCroix AZ. The role of heart disease prevention in women's decisions regarding hormone replacement Therapy, The EnPOWER Study. American Heart Association Scientific Session, November 1996.

Newton KM, LaCroix AZ, Woods NF, Keenan NL, Anderson LA. Decisions about hormone replacement therapy among HMO women in the 1900's. North American Menopause Society, 1996.

Newton KM, Ramsey SC, Wagner EH, McCulloch DK, Sandhu N. The use of automated data to evaluate the complication burden of diabetes in a managed care setting. American Diabetes Association, Boston, June, 1997.

Newton KM, LaCroix AZ, McKnight B, Knopp RH, Siscovick DS, Heckbert SK, Weiss NS. Estrogen replacement therapy and prognosis after first myocardial infarction. National Medical Association Scientific Sessions, Honolulu, August, 1997.

Newton KM, Anderson LA, LaCroix AZ, Buist DSM, Keenan NL. Healthcare provider characteristics and encouragement to use HRT: The EnPOWER Provider Survey. North American Menopause Society, Boston, September, 1997.

Newton KM, LaCroix AZ, Buist DSM. Do providers encourage HRT use for women at high risk of coronary disease? A focus on attitudes and prescribing behaviors. American Heart Association Scientific Session, November, 1997.

Newton KM. Conducting research in a managed care setting. School of Nursing, University of Washington, November, 1997.

Newton KM, LaCroix AZ, Buist DSM, Anderson LA, Keenan NL. What factors account for differences in HRT prescribing by healthcare providers? "The Future of Managed Care and Women's Health: New Directions for the 21st Century," The U.S. public Health Service's Office on Women's Health, Washington D.C., January 1998.

Newton KM, LaCroix AZ, Buist DSM, Anderson LA, Keenan NL. The physician's role in women's decision making about hormone replacement therapy – The EnPOWER provider survey. "The Future of Managed Care and Women's Health: New Directions for the 21st Century", The U.S. public Health Service's Office on Women's Health, Washington D.C., January 1998.

Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C. The use of automated data to identify complications and comorbidities of diabetes: A validation study. Cardiovascular Health Research Unit Works in Progress, Seattle, WA, February, 1998.

Newton KM, LaCroix AZ, Buist DSM. The use of alternative and complementary medicine by women enrolled in an HMO setting. HMO Research Network Conference. Oakland CA, May 8, 1998.

Newton KM. Obesity and postmenopausal hormones. Obesity: Impact on Cardiovascular Disease. American Heart Association. Amelia Island, Florida, May 1998.

Newton KM. The epidemiology of menopause. Reproductive Epidemiology, Department of Epidemiology, University of Washington, Seattle, WA, November 23, 1998.

Reed SD, **Newton KM**. Hormone replacement therapy (HRT) in ethnic minority populations. North American Menopause Society, New York, NY, September 21, 1999.

Newton KM, LaCroix AZ, Buist DSM Anderson LA. Will women in managed care use a mailed HRT workbook? The EnPower study workbook trial. North American Menopause Society, New York, NY, September 21, 1999.

LaCroix AZ, Anderson LA, **Newton KM**, Buist DSM. Qualities of HRT counseling: Findings from the EnPower study. North American Menopause Society, New York, NY, September 21, 1999.

Newton KM, Buist DSM, LaCroix AZ, Anderson LA. Attitudes towards uncertainty regarding HRT counseling: The EnPower Provider Survey. Orlando, FL, Sept 2000 (Poster)

Newton KM, LaCroix AZ, Heckbert SR, Wagner EH, McCulloch DK, Barlow WE. Estrogen replacement therapy is associated with reduced risk of death and cardiovascular events in women with type 2 diabetes. American Diabetes Association, San Francisco, CA, June 15, 2002.

Newton KM, Reed SD, Grothaus L, Ehrlich K, Guiltinan J, LaCroix AZ. The Herbal Alternative for Menopause Study: Factors associated with self reported severity of baseline vasomotor symptoms." Florence, Italy, April, 2004.

Newton, KM. "The Herbal Alternative HALT Study: A randomized trial of black cohosh, multibotanical herbs and dietary soy for vasomotor symptoms." Human Nutraceutical Research Unit, University of Guelph, Guelph, Ontario, Canada, March 29, 2006.

Newton KM, Buist DSM, Yu O, Hartsfield CL, Andrade, SE, Wei F, Connelly MT, Chan KA. Hormone Therapy Re-Initiation and First-Time Initiation by Type, Dose and Route, After the Women's Health Initiative. 7th European Congress on Menopause, Istanbul, Turkey, June 4, 2006.

Newton KM, Reed SD, Lee K, Grothaus LC, Ehrlich K, LaCroix AZ. The Impact of Hormone Therapy and Herbal Remedies for Menopause Symptoms on Sleep Quality: The HALT Trial. 7th European Congress on Menopause, Istanbul, Turkey, June 6, 2006.

Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Nekhlyudov L, Ludman EJ. Physician Approaches to HT Discontinuation. 8th European Congress on Menopause (EMAS), London, UK, May 19, 2009.

Newton KM, Buist, D, Anderson ML, Reed, SD, Bowles E. Who can quit? Factors Associated with Non-compliance with Short-term HT Suspension Prior to Screening Mammography. 8th European Congress on Menopause (EMAS), London, UK, May 19, 2009.

TEACHING EXPERIENCE

Formal Classroom Teaching

- 1977-1982 Lecturer/Research Instructor, Department of Physiological Nursing, University of Washington, Seattle, WA
- 1990-1993 Instructor, Epidemiologic Methods III
Department of Epidemiology, School of Public Health and Community Medicine
University of Washington, Seattle.

Teaching/Student Supervision

- 1999 Katherine Van Kessel MD, 3rd Year Resident, Obstetrics and Gynecology, University of Washington, "The Association Between Prolonged Second Stage of Labor and Stress Urinary Incontinence." GHC Consultant.
- 2000 Catherine Kim, MD, Robert Wood Johnson Scholar, Department of Epidemiology, University of Washington. Gestational Diabetes and Later Conversion to Type II Diabetes, A Population-Based Study. GHC Advisor.
- 2000 Sarah Cox, RN, Doctoral Student, Case Western University. Diet and Exercise in Mid-Life Women. GHC Consultant.
- 2001 Jennifer Brennen, MD, Robert Wood Johnson Scholar, Department of Epidemiology, University of Washington. Use of Alternative Therapies in Mid-Life Women". MPH Committee Member.
- 2002-2007 Michael Fialkow, MD, Senior Fellow, Departments of Urogynecology and Epidemiology, University of Washington. GHC Mentor.
- 2003-2007 Darcy Carr, MD, Department of Obstetrics and Gynecology, University of Washington. "Association between Pre-Eclampsia and Subsequent Type II Diabetes." GHC Mentor.
- 2004-present Jennifer Melville, MD, Departments of Obstetrics/Gynecology, Psychiatry, and Health Services, University of Washington, Mentored K Award. GHC Mentor.
- 2004 Audrey Warolin, RN, School of Nursing, University of Washington. ARNP Project Committee Member.

2005-present Leslie Spangler, DVM, PhD, Group Health Foundation Postdoctoral Fellow in Women's Health, Group Health Center for Health Studies. Mentor.